Interest in the potential of DNA methylation in peripheral blood as a biomarker of cancer risk is increasing. We aimed to assess whether epigenome-wide DNA methylation measured in peripheral blood samples obtained before onset of the disease is associated with increased risk of breast cancer. We report on three independent prospective nested case-control studies from the European Prospective Investigation into Cancer and Nutrition (EPIC-Italy; n = 162 matched case-control pairs), the Norwegian Women and Cancer study (NOWAC; n = 168 matched pairs), and the Breakthrough Generations Study (BGS; n = 548 matched pairs). We used the Illumina 450k array to measure methylation in the EPIC and NOWAC cohorts. Whole-genome bisulphite sequencing (WGBS) was performed on the BGS cohort using pooled DNA samples, combined to reach 50× coverage across ~16 million CpG sites in the genome including 450k array CpG sites. Mean β values over all probes were calculated as a measurement for epigenome-wide methylation.
Epigenome-wide association study reveals decreased average methylation levels years before breast cancer diagnosis / van Veldhoven, Karin; Polidoro, Silvia; Baglietto, Laura; Severi, Gianluca; Sacerdote, Carlotta; Panico, Salvatore; Mattiello, Amalia; Palli, Domenico; Masala, Giovanna; Krogh, Vittorio; Agnoli, Claudia; Tumino, Rosario; Frasca, Graziella; Flower, Kirsty; Curry, Ed; Orr, Nicholas; Tomczyk, Katarzyna; Jones, Michael E; Ashworth, Alan; Swerdlow, Anthony; Chadeau Hyam, Marc; Lund, Eiliv; Garcia Closas, Montserrat; Sandanger, Torkjel M; Flanagan, James M; Vineis, Paolo. - In: CLINICAL EPIGENETICS. - ISSN 1868-7083. - 7:(2015), p. 67. [10.1186/s13148-015-0104-2]
Epigenome-wide association study reveals decreased average methylation levels years before breast cancer diagnosis
PANICO, SALVATORE;
2015
Abstract
Interest in the potential of DNA methylation in peripheral blood as a biomarker of cancer risk is increasing. We aimed to assess whether epigenome-wide DNA methylation measured in peripheral blood samples obtained before onset of the disease is associated with increased risk of breast cancer. We report on three independent prospective nested case-control studies from the European Prospective Investigation into Cancer and Nutrition (EPIC-Italy; n = 162 matched case-control pairs), the Norwegian Women and Cancer study (NOWAC; n = 168 matched pairs), and the Breakthrough Generations Study (BGS; n = 548 matched pairs). We used the Illumina 450k array to measure methylation in the EPIC and NOWAC cohorts. Whole-genome bisulphite sequencing (WGBS) was performed on the BGS cohort using pooled DNA samples, combined to reach 50× coverage across ~16 million CpG sites in the genome including 450k array CpG sites. Mean β values over all probes were calculated as a measurement for epigenome-wide methylation.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
